Low-Dose Consolidation Radiation Therapy for Early-Stage Unfavorable Hodgkin Lymphoma

Abstract

The German Hodgkin Study Group (GHSG) HD11 trial established 4 cycles of ABVD and 30 Gy of radiation therapy (RT) as a standard for early-stage, unfavorable Hodgkin lymphoma (UF HL). HD11 also demonstrated that with 4 cycles of baseline BEACOPP, 20 Gy is as efficacious as 30 Gy. Additional cycles of ABVD may also allow for a reduction in RT dose. At our institution, patients often receive more than 4 cycles of ABVD for UF HL. If a complete response (CR) by positron emission tomography (PET) is achieved, ∼20 Gy of consolidation RT is typically administered.